Previous close | 38.40 |
Open | 38.40 |
Bid | 35.70 |
Ask | 37.55 |
Strike | 100.00 |
Expiry date | 2025-12-19 |
Day's range | 38.40 - 38.40 |
Contract range | N/A |
Volume | |
Open interest | 29 |
RAHWAY, N.J., May 15, 2024--Merck to Present New Data at 2024 ASCO Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.
RAHWAY, N.J., May 13, 2024--Merck Update on KeyVibe-010 Evaluating Coform of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients W/ Resected High-Risk Melanoma